newsfilter
← Latest News
Business Wire·

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

BMY
  • Bristol Myers Squibb presented 56-week results from the Phase 3 SCOUT-HCM clinical trial at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions on November 6, 2026, in Chicago.
  • The trial evaluated Camzyos (mavacamten) in pediatric patients aged 12 to <18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) weighing 30 kg or more.
  • No patient treated with Camzyos experienced a left ventricular ejection fraction (LVEF) below 50% during the 56-week evaluation period.
  • No new safety signals were reported, with treatment-emergent adverse events remaining low across both trial arms.
  • Patients in the mavacamten-mavacamten arm achieved a mean reduction of 48.1 mmHg in Valsalva LVOT gradient after 56 weeks of treatment.
  • Patients who switched from placebo to mavacamten showed similar significant reductions in LVOT gradient after the crossover period.
  • Camzyos is the first approved cardiac myosin inhibitor for pediatric patients with symptomatic oHCM, receiving FDA approval in September 2026.
  • Additional data supporting Camzyos efficacy & safety in adult populations will be presented at the American Heart Association's Scientific Sessions 2026.
  • The SCOUT-HCM trial was a randomized, double-blind, placebo-controlled study involving 44 pediatric participants across three treatment periods.
  • Camzyos is available only through a restricted REMS program due to the risk of heart failure & reduced LVEF.
  • Concomitant use of strong CYP2C19 inhibitors or moderate to strong CYP2C19/CYP3A4 inducers is contraindicated with Camzyos.
  • The drug is a selective, reversible inhibitor of cardiac myosin that targets hypercontractility to reduce LVOT obstruction & improve symptoms.